Drugs / VAX-31
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06151288 | Nov 2023 → Jul 2024 | — | Vaxcyte, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06720038 | Nov 2024 → Dec 2027 expected | — | Vaxcyte, Inc. | Active not recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07425392 | Feb 2026 → Mar 2027 expected | — | Vaxcyte, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07365826 | Jan 2026 → Mar 2027 expected | — | Vaxcyte, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07284654 | Dec 2025 → Jan 2027 expected | — | Vaxcyte, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VAX-31 | “Safety, tolerability, and immunogenicity of a 31-valent pneumococcal conjugate vaccine (VAX-31) in healthy adults aged 50 years and older from the USA: a phase 1/2,...” PMID 41864214 ↗ Mar 20264“Participants will receive a single dose of VAX-31 administered as an intramuscular injection at Day 1” NCT07365826 ↗ “Participants will receive a single dose of VAX-31 administered via intramuscular injection at Day 1” NCT07425392 ↗ “0.5 mL of VAX-31 will be administered into the deltoid muscle” NCT07284654 ↗ |
| Modality | Vaccine | “VAX-31, a 31-valent PCV candidate designed to provide broad serotype coverage and higher immunogenicity.” PMID 41864214 ↗ Mar 2026 |
| Route | Intramuscular | “Participants were block randomised (1:1:1:1) using a web-based randomisation and trial management system to receive a dose of intramuscular low-dose, mid-dose, or high-dose...” PMID 41864214 ↗ Mar 2026 |